Equity Research Analysis: SBC Medical Group Holdings Inc (SBC)
|Blank Capital Research Unit|Spot: $3.90
Price$3.90
Composite Score52.3/100
RatingHOLD (3★)
Rank#1647 OF 7,333
Market Cap$451M
IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1647
Positioning
Market Dominance
Services
Healthcare
$451M
Yoshiyuki Aikawa
SBC Medical Group Holdings, a Delaware corporation incorporated on January 20, 2023, is headquartered in Tokyo, Japan. SBC owns and provides management services to cosmetic treatment centers mainly in Japan.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = SBC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 17.1% | 10.3% | 35.5% | 14.6% | 10.1% | 105.2% | 0.0% | 41.0x | $244M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.1% | 8.3% | 45.7% | 8.5% | 6.2% | 28.1% | 0.0% | 0.0x | $736M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 0.0% | - | 97.4% | 58.0% | 37.4% | - | 8.8% | 264.0x | $2.5B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 15.3% | 5.8% | 100.0% | 6.9% | 5.2% | 15.1% | 0.0% | 24.0x | $1.8B | VS | |
$SBC SBC Medical Group Holdings Inc | 52 | 60 | 69 | 64 | 10.8x | 6.6x | 16.0% | 12.3% | 75.3% | 36.9% | 21.5% | -18.4% | 0.0% | 9.0x | $451M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.7% | 2.4% | 64.6% | 4.5% | 2.8% | 8.6% | 0.0% | 0.3x | - | REF |
SBC Medical Group Holdings Inc (SBC) receives a "Hold" rating with a composite score of 52.3/100. It ranks #1647 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for SBC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 60 | 74 | -14DRAG |
| MOMENTUM | 64 | 72 | -8DRAG |
| VALUATION | 69 | 80 | -11DRAG |
| INVESTMENT | 33 | 46 | -13DRAG |
| STABILITY | 57 | 61 | -4NEUTRAL |
| SHORT INT | 12 | 0 | +12ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 16.0% (sector 5.7%)
GM 75% vs sector 65%, OM 37% vs sector 5%
Capital turnover N/A
Rev growth -18%, 3yr history
Interest coverage 354.1x, Net debt/EBITDA -6.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate SBC Medical Group Holdings Inc (SBC) as a Hold with a composite score of 52.3/100 at a current price of $3.90. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
SBC Medical Group Holdings Inc holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.3/100 places it at rank #1647 in our full universe.
The near-term outlook is constructive, with revenue growing at -18% and momentum in the 64th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Narrow
Low
Exemplary
Undervalued
Gross margins of 75% signal strong pricing power.
Returns on equity of 16.0% exceed cost of capital.
Value factor score of 69 suggests attractive pricing.
Vulnerability to macroeconomic shocks and interest rate volatility.
SBC Medical Group Holdings Inc represents a hold based on multi-factor quantitative performance.
Our model assigns SBC Medical Group Holdings Inc a Hold rating, with a composite score of 52.3/100 and 3 out of 5 stars. Ranked #1647 of 7,333 stocks, SBC presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 60/100, SBC shows adequate but unremarkable business quality. The company reports a return on equity of 16.0% (sector avg: 5.7%), gross margins of 75.3% (sector avg: 64.6%), net margins of 21.5% (sector avg: 2.8%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
SBC's value score of 69/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 10.80x, an EV/EBITDA of 6.59x, a P/B ratio of 1.72x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
SBC Medical Group Holdings Inc's investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -18.4% vs. a sector average of 8.6% and a return on assets of 12.3% (sector: 2.4%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
SBC demonstrates moderate momentum with a score of 64/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -18.4% year-over-year, while a beta of 0.24 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 57/100, SBC exhibits average financial resilience. Key stability metrics include a beta of 0.24 and a debt-to-equity ratio of 9.00x (sector avg: 0.3x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
SBC Medical Group Holdings Inc's short interest score of 12/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 9.00x), small-cap liquidity risk. At $451M (small-cap), SBC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
SBC Medical Group Holdings Inc is a small-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #1647 of 7,333 overall (78th percentile). Key comparisons include ROE of 16.0% exceeding the 5.7% sector median and operating margins of 36.9% above the 4.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While SBC currently exhibits a HOLD profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Key factor gap
Value (69) vs Short Int. (12) — closing this gap could shift the rating.
EV/EBITDA 44% BELOW SECTOR MEDIAN (FAVORABLE)
ROE 178% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 16% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical" or the "Company"), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced that Medical Corporation Nasukai, a Japan-based medical corporation supported by SBC Medical and the operator of Shonan Beauty Clinic, has entered into a strategic business alliance with Daibi Medical Aesthetics, a medical aesthetic clinic based in Shanghai, China. The alliance aims
MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 & 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presen
TORONTO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (TSX: DGS, ESP, GDV, LBS, LCS, LCS.PR.A, SBC) – Brompton Funds announces distributions payable on February 13, 2026 to class A shareholders of record at the close of business on January 30, 2026 for each of the following funds: TickerAmount Per ShareDividend Growth Split Corp. (“DGS”)DGS$0.10Brompton Energy Split Corp. (“ESP”)ESP$0.10Global Dividend Growth Split Corp. (“GDV”)GDV$0.10Life & Banc Split Corp. (“LBS”)LBS$0.10Brompton Lifeco Split Corp. (“LC
Plans have been submitted which would see the site in Coldingham become a one-bedroom holiday let.